Отчет об анализе размера, доли и тенденций мирового рынка онтогенетической диагностики – обзор отрасли и прогноз до 2031 г.

Онтогенетический анализ рынка

Рынок онтогенеза переживает значительный рост, обусловленный достижениями в области генетических исследований и биотехнологий , фокусирующихся на манипулировании процессами развития на генетическом и клеточном уровнях. Этот рынок включает в себя передовые инновации, такие как редактирование генов, терапия стволовыми клетками и регенеративная медицина, все направленные на решение ряда медицинских и сельскохозяйственных задач. Использование CRISPR-Cas9 для точного редактирования генов, прогресс в регенеративной терапии на основе стволовых клеток и прорывы в биологии развития посредством передовой визуализации и биоинформатики раздвигают границы возможного. Такое расширение поддерживается увеличением финансирования исследований, растущим спросом на персонализированную медицину и непрерывным технологическим прогрессом, обещающим стимулировать существенный рост и предлагать преобразующие решения для ранее неразрешимых проблем.

Онтогенетический размер рынка

Объем мирового онтогенетического рынка оценивался в 1,84 млрд долларов США в 2023 году и, по прогнозам, достигнет 2,58 млрд долларов США к 2031 году со среднегодовым темпом роста 4,32% в прогнозируемый период с 2024 по 2031 год. Помимо информации о рыночных сценариях, таких как рыночная стоимость, темпы роста, сегментация, географический охват и основные игроки, рыночные отчеты, подготовленные Data Bridge Market Research, также включают в себя углубленный экспертный анализ, эпидемиологию пациентов, анализ воронки продаж, анализ цен и нормативную базу.

Тенденции рынка онтогенетических исследований

« Растущая интеграция технологий редактирования генов»

Яркой тенденцией онтогенетического рынка является растущая интеграция технологий редактирования генов, в частности CRISPR-Cas9, в биологию развития и регенеративную медицину. Такая тенденция отражает растущее внимание к точности и индивидуальности в лечении генетических нарушений и улучшении регенеративной терапии. Технология CRISPR-Cas9, известная своей способностью вносить точные изменения в ДНК, производит революцию в этой области, позволяя проводить целенаправленные вмешательства, которые могут исправлять генетические дефекты и влиять на процессы развития с высокой точностью. Такая тенденция дополнительно поддерживается достижениями в исследованиях стволовых клеток и регенеративной медицине, которые объединяются с редактированием генов для создания новых методов лечения ряда состояний, от врожденных заболеваний до возрастной дегенерации. Конвергенция таких технологий не только ускоряет исследования и разработки, но и расширяет потенциальные области применения онтогенетического рынка.

Область отчета и онтогенетическая сегментация рынка

Онтогенетическое определение рынка

Ontogenetic refers to the development or growth of an individual organism from the earliest stage to maturity. It encompasses the entire process of an organism's development, including embryonic development, maturation, and aging. Ontogenetic processes are concerned with how organisms grow and develop over time, including changes in their physical, physiological, and behavioral traits.

Ontogenetic Market Dynamics

Drivers

• Rising Prevalence of Genetic Disorders

The rising prevalence of genetic disorders and age-related conditions is a significant driver of the ontogenetic market, creating an escalating demand for effective therapies and solutions. Approximately 1 in 50 individuals is affected by a known single-gene disorder, while about 1 in 263 is impacted by a chromosomal disorder. Such high prevalence underscores the urgent need for innovative ontogenetic approaches to address complex genetic challenges. Such growing demand is propelling advancements in gene editing, stem cell research, and regenerative medicine, which aim to provide targeted, personalized treatments and improve patient outcomes. The continuous increase in these conditions highlights the necessity for ongoing research and development in ontogenetic therapies to meet the evolving healthcare needs of affected populations.

• Expansion Of Stem Cell Research

The expansion of stem cell research is a major driver of growth in the ontogenetic market, propelled by advancements in regenerative medicine and a deeper understanding of developmental processes. For instance, the development of induced pluripotent stem cells (iPSCs) has revolutionized the field by enabling researchers to reprogram adult cells into pluripotent states, which can differentiate into various cell types. Such ability to create and manipulate stem cells for the replacement of damaged tissues and organs underscores the transformative potential of stem cell research in regenerative medicine. As a result, this progress is driving substantial growth and innovation within the ontogenetic market, offering new avenues for treatment and significantly expanding the possibilities for addressing complex medical conditions.

Opportunities

• Application in Agricultural Biotechnology

Leveraging ontogenetic research can lead to the development of genetically modified crops with optimized growth patterns and improved resistance to pests and diseases. Advanced gene editing technologies, such as CRISPR-Cas9, are being used to precisely alter genes associated with yield and disease resistance, resulting in crops that can thrive under challenging environmental conditions. Moreover, ontogenetic insights can contribute to the enhancement of nutritional profiles by modifying metabolic pathways to increase the content of essential vitamins and minerals. For Instance, the development of biofortified crops such as Golden Rice, has been genetically engineered to produce higher levels of vitamin A. Such innovations not only improve crop yields and nutritional value but also play a crucial role in addressing global food security by ensuring a more resilient and nutritious food supply. Consequently broadening the ontogenetic market scope.

• Increased Investment In Biotechnology R&D

Increased investment in biotechnology research and development is creating substantial opportunities within the ontogenetic market. For instance, investment in India's bioeconomy increased 400%, reaching USD 507.77 million in 2022 from USD 1.20 million in 2014 reflecting a significant increase in funding directed towards innovative research and development. This influx of capital is enabling both startups and established companies to advance ontogenetic therapies and technologies. Such enhanced level of investments supports the development of cutting-edge ontogenetic therapies, such as targeted gene therapies and advanced regenerative treatments, which hold the potential to transform healthcare and address complex genetic and developmental conditions, creating substantial opportunities within the ontogenetic market.

Restraints/Challenges

• Complex Regulatory Landscape

Navigating the complex regulatory landscape for ontogenetic products is challenging due to varying standards and approval processes across regions. In the U.S., the FDA regulates gene editing tools and stem cell therapies through the Center for Biologics Evaluation and Research (CBER), requiring extensive preclinical and clinical data. Conversely, the European Medicines Agency (EMA) oversees advanced therapy medicinal products (ATMPS) through the committee for advanced therapies (CAT), adhering to regulation (EC) no 1394/2007, which imposes additional requirements. Consequently hindering the ontogenetic market growth.

• High Research Cost

High research costs pose a significant challenge in the ontogenetic market, as developing advanced products and technologies demands substantial investment. For instance, the creation of next-generation sequencing platforms, such as the Illumina NovaSeq X Plus, involves extensive research and development to enhance accuracy and throughput. This process requires millions of dollars for technology development, clinical trials, and regulatory approvals. Smaller companies and startups often struggle to secure the necessary funding to compete with established players who have the financial resources to invest in such high-cost projects. Consequently, the high cost of research and development can limit innovation and market entry for emerging firms, affecting the overall growth and diversification of the ontogenetic market.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Ontogenetic Market Scope

The market is segmented on the basis devices, application, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Devices

• Electroencephalography (EEG)
• Magnetoencephalography (MEG)
• Others

Application

• Developmental Biology
• Developmental Psychology
• Developmental Cognitive Neuroscience
• Developmental Psychobiology
• Others

End User

• Research Laboratories
• Academic Institutes
• Others

Ontogenetic Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, devices, application, and end user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

The north america region dominates the ontogenetic market due to substantial investments in research and development, as well as extensive clinical trials. Furthermore, the presence of leading research institutions and a strong focus on innovative therapies contribute significantly to its market leadership.

The asia-pacific region is anticipated to experience substantial growth from 2021 to 2028, driven by increased investment in research and development, coupled with government initiatives that promote and support scientific research. Additionally, the growing focus on innovation and technological advancements in the region is expected to further boost market expansion.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Ontogenetic Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Ontogenetic Market Leaders Operating in the Market Are:

• ANT Neuro (Netherlands)
• EMS Handels Gesellschaft m.b.H. (Austria)
• Natus (U.S.)
• Intelli Softwares Pte Ltd. (U.S.)
• Symbiotic Devices (Australia)
• Coherent Corp. (U.S.)
• Thorlabs Inc. (U.S.)
• Bruker (U.S.)
• Laserglow Technologies Inc. (Canada)
• GenSight Biologics (France)
• Judges Scientific plc (U.K.)
• Noldus Information Technology BV (Netherlands)

Latest Developments in Ontogenetic Market

• In October 2020, Novartis announced acquisition of Vedere Bio, enhancing its capabilities with a cutting-edge platform for AAV-based gene therapy delivery and a top-tier optogenetics program. This strategic acquisition reinforces Novartis's commitment to cell and gene therapy and will significantly advance its efforts to develop transformative treatments for vision loss and blindness. By integrating Vedere Bio's innovative technologies, Novartis aims to broaden its impact and provide groundbreaking therapies for patients suffering from blinding conditions.
• В сентябре 2021 года Novartis объявила о приобретении Arctos Medical, включив доклиническую программу генной терапии AAV на основе оптогенетики и фирменную технологию Arctos в свой офтальмологический портфель. Это приобретение подчеркивает приверженность Novartis разработке методов лечения потери зрения и подчеркивает потенциал оптогенетики как основы для эффективной терапии.

SKU-61280